Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
Cagrilintide
Metabolic & Weight Loss
Molecular Dossier
- Rank Index: 4
- Status: Phase 3 Clinical
- What does this mean?
- Molecular Structure: Acylated Amylin Analogue (C180H282N50O56S2)
About Cagrilintide
Cagrilintide (AMG 701) is a GIP/glucagon co-agonist in Phase 3 trials as a standalone agent and in combination with semaglutide (CagriSema). Once-weekly subcutaneous injection. Cagrilintide monotherapy Phase 2 trials showed 9–11% body weight reduction at therapeutic doses. CagriSema combination (semaglutide 2.4 mg + cagrilintide 2.4 mg) Phase 2b trials showed additive weight loss effects beyond semaglutide alone, reaching approximately 20% body weight reduction — positioning it between semaglutide (~15%) and tirzepatide (~22%) in efficacy. FDA regulatory submission for CagriSema was expected in 2025–2026, with potential approval in 2026–2027. The dual agonism (GIP + glucagon via cagrilintide) on top of GLP-1 (semaglutide) creates a potential "triple" mechanism mechanistically similar to retatrutide. As of May 2026, CagriSema represents an alternative path to high-potency weight loss compared to single retatrutide injections.
Clinical Focus
Weight Loss & Satiety
Archival Aliases
Cagri, Amylin Analog
Frequently Asked Questions
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
What is cagrilintide and how does it work?
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide co-secreted with insulin from pancreatic beta cells and plays a key role in appetite regulation, gastric emptying, and post-meal glucose control. Cagrilintide mimics and amplifies these effects, slowing gastric emptying, reducing food intake, and suppressing glucagon secretion — complementing GLP-1 mechanisms through a distinct receptor pathway.
What is the difference between cagrilintide alone and CagriSema?
Cagrilintide as a monotherapy shows moderate weight loss of approximately 10-11% over 26 weeks. CagriSema (cagrilintide + semaglutide in a fixed-dose combination injection) combines amylin and GLP-1 receptor agonism in a once-weekly injection. Phase 3 data for CagriSema shows weight reduction of 22-25% over 68 weeks, substantially exceeding either component alone due to complementary mechanisms.
What is the amylin receptor and where is it found?
The amylin receptor (AMY) is a Class B GPCR formed by the calcitonin receptor (CTR) combined with receptor activity-modifying proteins (RAMPs). AMY receptors are highly expressed in the brainstem (area postrema), hypothalamus, and nucleus accumbens — all regions critical to appetite regulation and food reward. Cagrilintide's sustained amylin agonism provides central appetite suppression independent of GLP-1 pathways.
Does cagrilintide affect lean mass loss?
Early Phase 3 data from CagriSema trials suggests that the combination may preserve lean mass better than GLP-1 monotherapy. Amylin is believed to selectively target fat mass for energy mobilization. Research is ongoing, but the dual mechanism combination appears to produce a more favorable fat-to-lean mass loss ratio — an important consideration given concerns about muscle loss with GLP-1 class drugs.
What are the side effects of cagrilintide?
The most common side effects parallel other weight-loss peptides: nausea, vomiting, diarrhea, and injection site reactions. At doses above 2.4mg weekly, nausea rates increase substantially. Hypoglycemia risk is low as a monotherapy but can increase in combination with insulin sensitizers. Phase 2/3 adverse event profiles are generally considered acceptable within the obesity drug class.
What is the approved dose of cagrilintide in trials?
Phase 3 CagriSema trials use cagrilintide at 2.4mg weekly combined with semaglutide 2.4mg weekly in a fixed-ratio combination. As a monotherapy, Phase 2 dose-finding explored 0.3mg to 4.5mg weekly. The 2.4mg dose represents the balance of efficacy and tolerability.
What conditions is cagrilintide being studied for beyond obesity?
Active research areas include Type 2 diabetes management, non-alcoholic fatty liver disease (NAFLD/MASH), cardiovascular disease prevention, and polycystic ovary syndrome (PCOS) — all conditions with a strong metabolic component where improved weight control and insulin sensitivity would be beneficial. CagriSema has received Fast Track designation from the FDA for obesity.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | Acylated Amylin Analogue (C180H282N50O56S2) |
| Primary Pathway | Metabolic & Weight Loss |
| Research Phase | Phase 3 Clinical |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-07